Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Medical management of Crohn's disease.

Literature DB >> 18467414

Medical management of Crohn's disease.

J R Fraser Cummings¹, Satish Keshav, Simon P L Travis.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2008 PMID： 18467414 PMCID： PMC2376027 DOI： 10.1136/bmj.39547.603218.AE

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

25 in total

1. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Authors: Edward V Loftus
Journal: Gastroenterology Date: 2004-05 Impact factor: 22.682

Review 2. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.

Authors: D S Rampton
Journal: Gut Date: 2005-08-19 Impact factor: 23.059

3. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

Authors: E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch
Journal: Gut Date: 2006-03 Impact factor: 23.059

4. Predictors of severe Crohn's disease.

Authors: Catherine Loly; Jacques Belaiche; Edouard Louis
Journal: Scand J Gastroenterol Date: 2008-08 Impact factor: 2.423

5. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.

Authors: J Markowitz; K Grancher; N Kohn; M Lesser; F Daum
Journal: Gastroenterology Date: 2000-10 Impact factor: 22.682

Review 6. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.

Authors: A K Akobeng; E Gardener
Journal: Cochrane Database Syst Rev Date: 2005-01-25

7. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Authors: Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn
Journal: Clin Gastroenterol Hepatol Date: 2006-05 Impact factor: 11.382

8. Predictors of Crohn's disease.

Authors: Laurent Beaugerie; Philippe Seksik; Isabelle Nion-Larmurier; Jean-Pierre Gendre; Jacques Cosnes
Journal: Gastroenterology Date: 2006-03 Impact factor: 22.682

9. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

Authors: A Bassi; S Dodd; P Williamson; K Bodger
Journal: Gut Date: 2004-10 Impact factor: 23.059

10. Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors: Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal: N Engl J Med Date: 2004-02-26 Impact factor: 91.245

17 in total

10. Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.

Authors: Xavier Roblin; Alain Attar; Michel Lamure; Bernard Savarieau; Pierre Brunel; Gérard Duru; Laurent Peyrin-Biroulet
Journal: J Mark Access Health Policy Date: 2015-10-30

Medical management of Crohn's disease.

1. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

Review 2. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.

3. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

4. Predictors of severe Crohn's disease.

5. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.

Review 6. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.

7. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

8. Predictors of Crohn's disease.

9. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

10. Infliximab maintenance therapy for fistulizing Crohn's disease.

Review 1. Management of arthropathy in inflammatory bowel diseases.

2. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

Review 3. Improving outpatient services: the Southampton IBD virtual clinic.

4. An unusual presentation of fistulating Crohn's disease: Ascites.

Review 5. Sleep disturbances and inflammatory bowel disease: a potential trigger for disease flare?

6. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States.

Review 7. Immunosuppressive therapies for inflammatory bowel disease.

8. Abdominal pain in an adult with Type 2 diabetes: A case report.

Review 9. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.

10. Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.